冠心舒通胶囊联合阿托伐他汀治疗急性心肌梗死合并H型高血压的临床效果  

Clinical Effect of Guanxin Shutong Capsules and Atorvastatin in the Treatment of Acute Myocardial Infarction and H-type Hypertension

作　　者：彭轩宇 孟庆贺 PENG Xuanyu;MENG Qinghe(Mudanjiang Medical University,Mudanjiang 157011,China;不详)

机构地区：[1]牡丹江医科大学,黑龙江牡丹江157011

出　　处：《中国医学创新》2024年第33期10-14,共5页Medical Innovation of China

摘　　要：目的:探讨急性心肌梗死(AMI)合并H型高血压(HHT)患者采用冠心舒通胶囊联合阿托伐他汀治疗的临床效果。方法:选取2021年4月—2024年1月牡丹江医科大学附属第二医院收治的AMI合并HHT患者共计88例,以随机数字表法分成研究组(44例)与对照组(44例),对照组采用阿托伐他汀治疗,研究组采用冠心舒通胶囊联合阿托伐他汀治疗,比较两组心肌梗死溶栓试验(TIMI)血流分级、心肌酶谱指标、血清指标、不良反应、主要不良心血管事件(MACE)。结果:治疗后,研究组TIMI血流分级优于对照组,差异有统计学意义(P<0.05);两组治疗后乳酸脱氢酶(LDH)、肌钙蛋白I(cTnI)水平均下降,研究组均较对照组更低,差异均有统计学意义(P<0.05);两组治疗后白细胞介素-8(IL-8)、血管细胞黏附分子-1(VCAM-1)、生长分化因子-15(GDF-15)水平均下降,研究组均较对照组更低,差异均有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05);统计MACE发生率,研究组(9.09%)较对照组(27.27%)更低,差异有统计学意义(P<0.05)。结论:AMI合并HHT患者采用冠心舒通胶囊联合阿托伐他汀治疗,可有效改善血流灌注状态、心肌酶谱指标、血清指标,减少MACE,且安全性较高。Objective:To explore the clinical efficacy of Guanxin Shutong Capsules and Atorvastatin in patients with acute myocardial infarction(AMI)and H-type hypertension(HHT).Method:A total of 88 patients with AMI and HHT from April 2021 to January 2024 who were admitted in Mudanjiang Medical University Affiliated Second Hospital were selected and randomly divided into the study group(44 cases)and the control group(44 cases).The control group was treated with Atorvastatin,the study group was treated with Guanxin Shutong Capsules and Atorvastatin.The myocardial infarction thrombolysis test(TIMI)blood flow grading,myocardial enzyme spectrum indicators,serum indicators,adverse reactions,and major adverse cardiovascular events(MACE)were compared between the two groups.Result:After treatment,in the TIMI blood flow grading,in comparison of the control group,that in the study group was better,the difference was statistically significant(P<0.05).After treatment,the lactate dehydrogenase(LDH)and cardiac troponin I(cTnI)in both groups were decreased,and in comparison of the control group,those in the study group were lower,the differences were statistically significant(P<0.05).After treatment,the interleukin-8(IL-8),vascular cell adhesion molecule-1(VCAM-1),growth differentiation factor-15(GDF-15)levels in both groups were decreased,and in comparison of the control group,those in the study group were lower,the differences were statistically significant(P<0.05).In the incidence of adverse reactions,there was no statistically significant difference in both groups(P>0.05).In the incidence of MACE,in comparison of the control group(27.27%),that in the study group(9.09%)was lower,the difference was statistically significant(P<0.05).Conclusion:Treatment with Guanxin Shutong Capsules and Atorvastatin in AMI patients with HHT can effectively improve blood perfusion status,myocardial enzyme spectrum indicators,serum indicators,reduce MACE,and has high safety.

关 键 词：冠心舒通胶囊 阿托伐他汀 急性心肌梗死 H型高血压 

分 类 号：R542.22[医药卫生—心血管疾病] R544.1[医药卫生—内科学]